← All trials
NCT01027884
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2009
- Primary completion
- Jan 1, 2014
- Completion date
- Apr 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 65
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- SantheraLead sponsor
- University of FloridaOverall official - principal investigator
- University of California, DavisOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- Fondazione IRCCS Eugenio MedeaOverall official - principal investigator
- Leiden UniversityOverall official - principal investigator
- The Charlotte-Mecklenburg Hospital AuthorityOverall official - principal investigator
- University of ColoradoOverall official - principal investigator
- Vanderbilt UniversityOverall official - principal investigator
- University of PennsylvaniaOverall official - principal investigator
- Katholieke Universiteit LeuvenOverall official - principal investigator
- Karolinska InstituteOverall official - principal investigator
- University of MilanOverall official - principal investigator
- Methodist Cancer Center, Houston, TexasOverall official - principal investigator
- The University of Texas, DallasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.